Less than a tenth of people eligible to benefit from obesity jabs including Wegovy can access them, states the World Health Organization as it publishes its first advice on the therapies.
Considering over a billion individuals worldwide now obese, it is calling for broader and more equitable access to this class of drugs.
According to estimates, in excess of 2,000,000,000 are projected to be obese by 2030 unless action is taken.
"The latest guidance affirms that obesity is a long-term condition that can be treated with thorough and continuous treatment," stated its chief Tedros Adhanom Ghebreyesus.
High costs, insufficient output, and logistical bottlenecks are major barriers to broad access to the jabs that can aid individuals in losing significant body mass, explains the agency.
GLP-1 Therapy Supply Crisis
Even under the present best projected scenario, the manufacturing of these medications would only suffice for about 100 million people – less than 10% of the global need, as stated by the health organization.
The guideline calls on countries and companies to increase access, by strategies such as licensing agreements.
Exclusive production rights on a key compound – the main component of the drug Wegovy – is scheduled to end in a number of nations in 2026.
The Way Weight-Loss Injections Function
The injections mimick a biological compound to delay gastric emptying, curb appetite and enhance satiety so users consume fewer calories.
Individuals commonly see weight reduction within a few weeks of beginning the once-weekly jabs.
Studies suggests users may put most of the weight back on after a year of stopping the medication, when their typical appetite return.
Being carrying excess weight elevates your chance for developing medical conditions, such as type 2 diabetes, heart disease, stroke, and certain malignancies.
Obesity impacts people in countries worldwide and was responsible for 3.7 million fatalities worldwide in 2024, as per the health agency.
